Spots Global Cancer Trial Database for carcinoma, small cell lung
Every month we try and update this database with for carcinoma, small cell lung cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer | NCT03871205 | Carcinoma, Non-... Carcinoma, Smal... | Neoantigen load... | 18 Years - 70 Years | Shenzhen People's Hospital | |
| Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer | NCT04622228 | Carcinoma, Smal... | Atezolizumab Cisplatin Carboplatin Etoposide Thoracic radiat... | 18 Years - | Hoffmann-La Roche | |
| Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer | NCT00294931 | Carcinoma, Smal... | irinotecan carboplatin bevacizumab | 18 Years - | SCRI Development Innovations, LLC | |
| Study of AZD2811 + Durvalumab in ES-SCLC | NCT04745689 | Small-Cell Lung... | Durvalumab AZD2811 Carboplatin Cisplatin Etoposide | 18 Years - 130 Years | AstraZeneca | |
| Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | NCT01306045 | Carcinoma, Non-... Carcinoma, Smal... Carcinoma, Thym... | AZD6244 MK-2206 Lapatinib Erlotinib Sunitinib Molecular Profi... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer | NCT04622228 | Carcinoma, Smal... | Atezolizumab Cisplatin Carboplatin Etoposide Thoracic radiat... | 18 Years - | Hoffmann-La Roche | |
| PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | NCT02936323 | Neuroendocrine ... Carcinoma, Smal... Neuroendocrine ... | PEN-221 PEN-221 | 18 Years - | Tarveda Therapeutics | |
| Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) | NCT03043872 | Small Cell Lung... | Durvalumab Tremelimumab Carboplatin Cisplatin Etoposide | 18 Years - 130 Years | AstraZeneca | |
| Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer | NCT00308529 | Carcinoma, Smal... Lung Cancer | irinotecan carboplatin bevacizumab Radiation Thera... | 18 Years - | SCRI Development Innovations, LLC | |
| Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer | NCT00308529 | Carcinoma, Smal... Lung Cancer | irinotecan carboplatin bevacizumab Radiation Thera... | 18 Years - | SCRI Development Innovations, LLC | |
| N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy | NCT00637624 | Carcinoma, Non-... Carcinoma, Smal... Mesothelioma | N-Acetylcystein... Placebo | 18 Years - | Rijnstate Hospital | |
| Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer | NCT03871205 | Carcinoma, Non-... Carcinoma, Smal... | Neoantigen load... | 18 Years - 70 Years | Shenzhen People's Hospital | |
| Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer. | NCT04253145 | Carcinoma, Smal... | PM 01183 Atezolizumab | 18 Years - 80 Years | Fundacion Oncosur | |
| A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer | NCT04308785 | Carcinoma, Smal... | Atezolizumab Tiragolumab Placebo | 18 Years - | Hoffmann-La Roche | |
| Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) | NCT03043872 | Small Cell Lung... | Durvalumab Tremelimumab Carboplatin Cisplatin Etoposide | 18 Years - 130 Years | AstraZeneca | |
| Study of AZD2811 + Durvalumab in ES-SCLC | NCT04745689 | Small-Cell Lung... | Durvalumab AZD2811 Carboplatin Cisplatin Etoposide | 18 Years - 130 Years | AstraZeneca | |
| The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy | NCT00270166 | Anemia Multiple Myelom... Lymphoma Breast Cancer Ovarian Cancer Carcinoma, Smal... Esophagus Cance... Prostate Cancer Neoplasm | epoetin alfa | 18 Years - 80 Years | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer | NCT03083691 | Carcinoma, Non-... Carcinoma, Smal... | Nivolumab, Ipil... Nivolumab, Ipil... | 18 Years - | Lung Cancer Group Cologne | |
| Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer | NCT00308529 | Carcinoma, Smal... Lung Cancer | irinotecan carboplatin bevacizumab Radiation Thera... | 18 Years - | SCRI Development Innovations, LLC | |
| Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG | NCT00037713 | Carcinoma, Smal... | BEC2 Vaccine | 18 Years - | Eli Lilly and Company | |
| Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer | NCT00265200 | Carcinoma, Non-... Carcinoma, Smal... Metastases | zoledronic acid | 18 Years - | University of Louisville | |
| Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs | NCT04985357 | Stage III Breas... Stage IV Breast... Stage III Lung ... Stage IV Lung C... AML Multiple Myelom... Carcinoma Carcinoma, Panc... Carcinoma of Lu... Carcinoma, Non-... Carcinoma Breas... Carcinoma Prost... Carcinoma, Hepa... Carcinoma, Rena... Carcinoma, Neur... Carcinoma, Smal... Carcinoma, Ovar... Carcinoma Bladd... Carcinoma of Es... Carcinoma Cervi... Carcinoma, Thym... Carcinoma, Duct... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of Un... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Malignant Pleur... Malignant Ascit... Mesothelioma Cholangiocarcin... | 18 Years - | Travera Inc | ||
| Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma | NCT00435578 | Carcinoma, Smal... | Glufosfamide | 18 Years - | Threshold Pharmaceuticals | |
| Metabolomic Analysis of Lung Cancer | NCT00263731 | Carcinoma, Non-... Carcinoma, Smal... | 13-C-glucose | 18 Years - 75 Years | University of Louisville | |
| Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG | NCT00037713 | Carcinoma, Smal... | BEC2 Vaccine | 18 Years - | Eli Lilly and Company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
